20 studies found for:    Open Studies | "Tuberous Sclerosis"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Tuberous Sclerosis"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Tuberous Sclerosis Complex Natural History Study: Renal Manifestations
Condition: Tuberous Sclerosis Complex
2 Recruiting Study of Skin Tumors in Tuberous Sclerosis
Conditions: Hereditary Neoplastic Syndrome;   Tuberous Sclerosis
3 Recruiting Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
Conditions: Renal Angiomyolipomas;   Tuberous Sclerosis
Intervention: Drug: Propranolol
4 Recruiting Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
Conditions: Tuberous Sclerosis;   Autism Disorder;   Intellectual Disability
5 Recruiting A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
Condition: Tuberous Sclerosis
Interventions: Drug: Placebo;   Drug: Everolimus (RAD001)
6 Recruiting Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)
Condition: Tuberous Sclerosis Complex
7 Recruiting Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
Conditions: Tuberous Sclerosis Complex;   TSC Related Cognitive Disability;   TSC Related Autism;   TSC Related Learning Problems
Interventions: Drug: Everolimus;   Drug: Placebo
8 Recruiting Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
Conditions: TSC;   Tuberous Sclerosis Complex;   Epilepsy
Intervention: Device: epilepsy early diagnosis protocol
9 Not yet recruiting Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
Conditions: Tuberous Sclerosis;   Lymphangioleiomyomatosis;   Angiomyolipoma
10 Not yet recruiting A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Focal Seizures in Tuberous Sclerosis Complex.
Conditions: Tuberous Sclerosis Complex;   Seizures, Focal
Interventions: Drug: GWP42003-P;   Drug: Placebo
11 Not yet recruiting An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Focal Seizures in Tuberous Sclerosis Complex.
Conditions: Tuberous Sclerosis Complex;   Seizures, Focal
Intervention: Drug: GWP42003-P
12 Recruiting Safety of Simvastatin in LAM and TSC
Conditions: Lymphangioleiomyomatosis;   Tuberous Sclerosis Complex
Intervention: Drug: Simvastatin
13 Recruiting The Cognitive Variability in NF1 and TSC Monozygotic Twins
Conditions: Neurofibromatosis Type I;   Tuberous Sclerosis Complex
14 Recruiting A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
Conditions: Epilepsy;   Tuberous Sclerosis Complex;   Focal Cortical Dysplasia
Intervention: Drug: Everolimus
15 Recruiting Study of the Disease Process of Lymphangioleiomyomatosis
Conditions: Lung Disease;   Pneumothorax;   Tuberous Sclerosis
16 Recruiting Everolimus for Cancer With TSC1 or TSC2 Mutation
Conditions: TSC1;   TSC2;   Tuberous Sclerosis Complex;   MTOR
Intervention: Drug: Everolimus
17 Recruiting Role of Genetic Factors in the Development of Lung Disease
Conditions: Cystic Fibrosis;   Sarcoidosis;   Tuberous Sclerosis;   Asthma
18 Recruiting Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream
Condition: Facial Angiofibroma
Intervention: Drug: Rapamune
19 Unknown  Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients
Condition: Complex Partial Seizures
Intervention: Drug: vigabatrin
20 Recruiting Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
Condition: Sleep Disorders
Interventions: Drug: Circadin 2/5/10 mg;   Drug: Placebo

Indicates status has not been verified in more than two years